Skip to main content

Table 1 Patients characteristics

From: Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

  N %
Age Median: 59 y (37–84)
Cycles of CT: 3 (1–7)
BM 22 100
 Parenchymal 17 77
 Leptomeningeal 8 36
Lines prior of CT
 ≤ 3 8 36
 > 3 14 64
HER-2 status
 Positive 13 59
 Negative 8 36
 Not Known 1 5
Hormone Receptors status
 Positive 11 50
 Negative 10 45
 Not Known 1 5
Triple Negative 2 9
CNS Radiotherapy
 Yes 15 68
 No 7 32
Other site of metastases
 Yes 20 81
 No 2 9
Concomitant treatment
 Yes 14 64
  Trastuzumab intravenous 11 50
  MTX intrathecal 2 9
  Lapatinib 1 5
 No 7 32
\